中國生物製藥(01177.HK)年度純利微增0.3%至27.71億元 末期息2港仙
格隆匯3月23日丨中國生物製藥(01177.HK)公佈,截至2020年12月31日止年度,公司收入約人民幣236.47億元,較去年輕微下降約2.4%;歸屬於母公司持有者應占盈利約人民幣27.71億元,較去年輕微增長約0.3%;每股基本盈利約人民幣14.74分,末期股息每股2港仙。
期間新產品銷售佔集團總收入約38.1%,達到約人民幣90.1億元,較去年上升約79.3%。抗腫瘤用藥銷售額約人民幣76.2億元,較去年上升約40.3%。
一直以來,集團十分重視研發,以結合自主創新、聯合開發及創仿開發的研發理念,不斷提升研發水平和速度,並視其為可持續發展的基礎,加大研發的資金投入。該年度,研發總開支約人民幣28.5億元,佔集團收入約12.1%,已計入損益表及資本化於財務狀況表中。
集團繼續專注肝病、抗腫瘤、呼吸系統和心腦血管等治療領域的新產品研發。於第四季度內,集團獲得臨牀批件5件、生產批件12件及一致性評價獲批23個、申報臨牀6件、一致性評價申報2個及申報生產4個。已累計有臨牀批件、正在進行臨牀試驗和申報生產的在研產品共391件,其中肝病用藥39件、抗腫瘤用藥183件、呼吸系統用藥22件、內分泌用藥20件、心腦血管用藥16件及其它類用藥111件。集團已累計獲得發明專利授權924項、授權實用新型專利31項,以及授權外觀設計專利115項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.